PRCT PROCEPT BioRobotics (PRCT) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001588978
C-suite buying · 1Form 144 · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
141
13F, latest reported quarter
What the filings say about PRCT
Insiders, 180 days
+$448.0K net bought
1 buyer · 3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$21.9K
3 notices
PROCEPT BioRobotics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, PROCEPT BioRobotics Corp insiders bought a net $448.0K of stock across 187 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Jun 8, 2026.
- The trade is 0.2% of the 180,355 shares held after it.
- 2 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CFO Waters Kevin sold about $7.8K of PRCT on Sep 9, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 8, 2026.
- The trade is 0.4% of the 94,826 shares held after it.
- 2 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Technology Officer Templin Barry L sold about $7.8K of PRCT on Sep 9, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.Context
- 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Jun 8, 2026.
- The trade is 0.2% of the 127,737 shares held after it.
- 2 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CLO, CORP. SEC. Nouri Alaleh sold about $6.2K of PRCT on Sep 9, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 23,900 shares held after it.
- No other insider bought within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO Wood Larry L bought about $498.3K of PRCT on Aug 7, 2026; 141 funds added in the latest 13F quarter.Context
- 34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Mar 19, 2026.
- The trade is 0.3% of the 105,069 shares held after it.
- 2 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CLO, CORP. SEC. Nouri Alaleh sold about $8.1K of PRCT on Jun 8, 2026; 2 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.187 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$448.0K over 180 days
+$476.5K over 90 days
more than 86% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
141 funds bought in last quarter
more than 72% of Medical Devices
Revenue
+37.2% year over year
more than 84% of Medical Devices
Margin
-31.0% net margin
below 60% of Medical Devices
Buybacks
no share repurchases reported
Short interest
13.3% of the float short (float per yahoo 2026-10-26) · 5.3 days to cover · settled 2026-09-30
more than 93% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PRCT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-43.1%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PRCT: institutional holders (13F)
13F holdings, latest reported quarter
4,869,828 sh
$110.0M
2,823,849 sh
$63.8M
2,526,802 sh
$57.1M
2,460,802 sh
$55.6M
2,073,237 sh
$46.8M
Congress trades in PRCT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PRCT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Nouri Alaleh
Filed 2026-09-09
$6.2K
Waters Kevin
Filed 2026-09-09
$7.8K
Templin Barry L
Filed 2026-09-09
$7.8K
PRCT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Taylor Frigon Core Growth Fund
$686.5K position · as of 2026-05-31
1.9%
Global X HealthTech ETF
$348.3K position · as of 2026-05-31
1.4%
VELA SMALL CAP FUND
$2.3M position · as of 2026-06-30
1.3%
Rockefeller US Small Cap Core Fund
$1.3M position · as of 2026-05-31
1.3%
AlphaCentric Robotics and Automation Fund
$338.7K position · as of 2026-06-30
1.3%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$1.9M position · as of 2026-06-30
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
6
Not applicable
3 active
What changed recently
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
2026-09-03 · Active Not Recruiting → Unknown
Not applicable
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Reza Zadno Ph.D
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$6.5M
$17.8M
$2.8M
+92%
-3%
2023
$6.1M
$2.3M
$2.5M
-0%
-13%
2022
$4.1M
$19.4M
$1.1M
-1%
-20%
2021
$1.4M
$23.1M
$834.6K
-40%
-2%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $448.0K bought by insiders over 180 days, 141 funds added last quarter, $21.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
PRCT financials
Revenue growth
+37.2%
XBRL, annual
Net margin
-31.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$337.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PRCT
| FY Dec 2025 | $308.1M |
| FY Dec 2024 | $224.5M |
| FY Dec 2023 | $136.2M |
| FY Dec 2022 | $75.0M |
| FY Dec 2021 | $34.5M |
| Jun 2026 | $94.5M |
| Mar 2026 | $83.1M |
| Dec 2025 | $76.4M |
| Sep 2025 | $83.3M |
| Jun 2025 | $79.2M |
| Mar 2025 | $69.2M |
| Dec 2024 | $68.2M |
| Sep 2024 | $58.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-4.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PRCT
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -0.1% |
| FY Dec 2021 | -0.2% |
| Jun 2026 | -28.4% |
| Mar 2026 | -38.1% |
| Dec 2025 | +85.9% |
| Sep 2025 | -25.7% |
| Jun 2025 | -24.7% |
| Mar 2025 | -35.8% |
| Dec 2024 | +106.2% |
| Sep 2024 | -35.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$84.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PRCT
| FY Dec 2025 | -$58.3M |
| FY Dec 2024 | -$103.6M |
| FY Dec 2023 | -$133.2M |
| FY Dec 2022 | -$83.0M |
| FY Dec 2021 | -$57.9M |
| Jun 2026 | -$22.2M |
| Mar 2026 | -$41.0M |
| Dec 2025 | -$12.2M |
| Sep 2025 | -$9.5M |
| Jun 2025 | -$17.8M |
| Mar 2025 | -$18.8M |
| Dec 2024 | -$33.6M |
| Sep 2024 | -$19.0M |
At each fiscal year end
Single quarter
Debt to equity
0.15x
long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end); equity 2026-06-30
Debt to equity PRCT
| FY Dec 2025 | 0.14x |
| FY Dec 2024 | 0.13x |
| FY Dec 2023 | 0.18x |
| FY Dec 2022 | 0.26x |
| FY Dec 2021 | 0.19x |
| Jun 2026 | 0.15x |
| Mar 2026 | 0.15x |
| Dec 2025 | 0.14x |
| Sep 2025 | 0.14x |
| Jun 2025 | 0.13x |
| Mar 2025 | 0.13x |
| Dec 2024 | 0.13x |
| Sep 2024 | 0.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.44x
TTM operating cash flow over long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end)
Cash flow to debt PRCT
| FY Dec 2025 | -0.95x |
| FY Dec 2024 | -1.93x |
| FY Dec 2023 | -2.10x |
| FY Dec 2022 | -1.57x |
| FY Dec 2021 | -1.15x |
| Jun 2026 | -1.44x |
| Mar 2026 | -1.36x |
| Dec 2025 | -0.95x |
| Sep 2025 | -1.38x |
| Jun 2025 | -1.62x |
| Mar 2025 | -1.63x |
| Dec 2024 | -1.93x |
| Sep 2024 | -1.78x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-3.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PRCT
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | -3.9% |
| Mar 2026 | -1.9% |
| Dec 2025 | -0.0% |
| Sep 2025 | +2.2% |
| Jun 2025 | +2.3% |
| Mar 2025 | +0.3% |
| Dec 2024 | -0.0% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-2.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PRCT
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | -0.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | -0.0% |
| Jun 2026 | -2.9% |
| Mar 2026 | -1.4% |
| Dec 2025 | -0.0% |
| Sep 2025 | +1.5% |
| Jun 2025 | +1.6% |
| Mar 2025 | +0.3% |
| Dec 2024 | -0.0% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PRCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-26.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PRCT
| FY Dec 2025 | -22.5% |
| FY Dec 2024 | -23.0% |
| FY Dec 2023 | -34.5% |
| FY Dec 2022 | -27.1% |
| FY Dec 2021 | -25.1% |
| Jun 2026 | -26.0% |
| Mar 2026 | -24.5% |
| Dec 2025 | -22.5% |
| Sep 2025 | -23.8% |
| Jun 2025 | -23.1% |
| Mar 2025 | -23.8% |
| Dec 2024 | -23.0% |
| Sep 2024 | -30.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PRCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$967.0M
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end), minus cash 2026-06-30
Enterprise value PRCT
| FY Dec 2025 | $1.5B |
| FY Dec 2024 | $3.9B |
| FY Dec 2023 | $1.9B |
| FY Dec 2022 | $1.7B |
| FY Dec 2021 | $833.5M |
| Jun 2026 | $1.1B |
| Mar 2026 | $1.2B |
| Dec 2025 | $1.5B |
| Sep 2025 | $1.7B |
| Jun 2025 | $2.9B |
| Mar 2025 | $2.9B |
| Dec 2024 | $3.9B |
| Sep 2024 | $4.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-7.4%
TTM free cash flow over market value at close 2026-10-23
FCF yield PRCT
| FY Dec 2025 | -3.3% |
| FY Dec 2024 | -2.5% |
| FY Dec 2023 | -6.3% |
| FY Dec 2022 | -4.5% |
| FY Dec 2021 | -5.3% |
| Jun 2026 | -6.6% |
| Mar 2026 | -5.7% |
| Dec 2025 | -3.3% |
| Sep 2025 | -4.0% |
| Jun 2025 | -2.8% |
| Mar 2025 | -2.8% |
| Dec 2024 | -2.5% |
| Sep 2024 | -2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PRCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $308.1M | $224.5M | $136.2M | $75.0M |
| Gross profit | $196.2M | $137.1M | $71.0M | $37.1M |
| Operating income | -$103.9M | -$96.6M | -$109.2M | -$80.7M |
| Net income | -$95.6K | -$91.4K | -$105.9K | -$87.2K |
| EPS (diluted) | n/a | n/a | n/a | n/a |
| Operating cash flow | -$49.0M | -$99.2M | -$108.0M | -$80.4M |
| Cash | $286.5M | $333.7M | $257.2M | $221.9M |
| Long-term debt | $51.6M | $51.5M | $51.3M | $51.2M |
SEC XBRL, fiscal years, as known on 2026-10-27
PRCT Stock Sonar score 6/7 axes
Find similar shapesComparePRCT ranks highest on growth (84th percentile) and insider conviction (69th), and lowest on financial health (45th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PRCT filings, in plain words
Are PROCEPT BioRobotics insiders buying or selling PRCT?
In the 180 days to 2026-10-27, PROCEPT BioRobotics insiders were net buyers, a net $448.0K: $498.3K of purchases and $50.3K of sales reported on Form 4, by 1 buyer and 3 sellers.
Are there planned insider sales of PRCT?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $21.9K of stock; the latest, by Nouri Alaleh, was filed 2026-09-09.
Read the full summary
In the 180 days to 2026-10-27, PROCEPT BioRobotics insiders were net buyers of PRCT, a net $448.0K across purchases and sales reported on Form 4 by 1 buyer and 3 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $21.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
